Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

近年来，美国国立卫生研究院每年向众多研究机构和医院拨款超过8.5亿美元 在德克萨斯医疗中心(TMC；德克萨斯州休斯顿)内，生产的生物医学发现数量不断增加- 查理斯。尽管有如此巨大的投资，但这些发现中只有一部分进入了临床，甚至更少 已成功商业化，以改善患者的健康和福祉。德克萨斯州学术企业家面临 在他们寻求将他们的发现商业化时面临的重大挑战，包括缺乏培训和资源 支持早期业务和技术发展。为了解决这些不足之处，我们将建立 墨西哥湾沿岸财团研究评估和商业化枢纽(GCC-REACH)作为一个国际- 新兴的学术创业者与成功的人生紧密合作的多机构资源 科学专家和经验丰富的生物技术高管制定战略里程碑驱动的时间表，以快速 验证他们的发现的商业价值。GCC-REACH将扩大GCC和TMC的基础设施 以及我们为支持新兴生物医药公司而设计的资源。学院派企业家将欢呼 来自所有GCC附属机构(贝勒医学院，德克萨斯州农工健康科学中心，休斯顿 卫理公会研究院，MD安德森癌症中心，莱斯大学，德克萨斯南方大学，Univer- 休斯顿大学，德克萨斯大学健康科学中心，德克萨斯大学医学分校)，休斯顿- 拥有大量历史上代表性不足的群体的地区学院和大学，以及其他德克萨斯州研究机构- 辅导课。GCC-REACH计划将提供管理监督、获得审查的资源和种子 资金，协助每一位企业家迈向明确的增值商业化拐点。 意义重大。与众多德克萨斯州的研究人员讨论，所有GCC附属的技术转让- FICS、成功的生命科学公司和医疗保健投资者都表示广泛支持这一点 倡议，指出这将有助于成立新的公司和推进生物医学发现。重要的是 GCC-REACH将与平衡全职临床、教学和实验室职责与EIR的企业家配对 以及专家团队，他们将在完成市场分析、业务计划、 和技术发展战略。 价值主张。再加上大量的多机构支持，NIH的400万美元投资将使 GCC-REACH培训学术企业家，使其成功地将新发现商业化。我们期待着这些 创业者将推出大约60家具有高度竞争力的早期生物医药公司，这些公司将 在非稀释性NIH SBIR/STTR融资和风险投资方面具有极强的竞争力。

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discov- eries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face significant challenges as they seek to commercialize their discoveries, including a lack of training and resources to support early-stage business and technology development. To address these deficiencies, we will establish the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an inte- grated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, Univer- sity of Houston, the University of Texas Health Science Center, University of Texas Medical Branch), Houston- area colleges and universities with large historically-underrepresented groups, and other Texas research insti- tutions. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point. Significance. Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer of- fices, successful life science companies, and healthcare investors have indicated widespread support for this initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly, GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs and expert teams who will provide mentorship and assistance in completing the market analysis, business plans, and technology development strategies. Value proposition. In combination with substantial multi-institutional support, NIH's $4M investment will enable GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.